Johnson & Johnson's vaccine, which has been recently approved for use in the US, differs from those already in use in the EU in that it is administered in a single shot.
"Today, we aren't dependent solely on AstraZeneca any more. We'll soon have a fourth manufacturer," he told reporters after visiting a new vaccination center in Kaunas. "Johnson & Johnson (...) should be licensed in Europe in March, too."
The Lithuanian Health Ministry said earlier on Monday that AstraZeneca had notified it that it would deliver around 26 percent less vaccines in the next six months than preliminary planned.
Commenting on the news, Nauseda said, "I wouldn’t make any far-reaching conclusions from such one-off announcements", adding that EU leaders have been pressing the European Commission "to negotiate tough with vaccine manufacturers (...) to make sure that they fulfil their obligations".
The president added that mass vaccination is the only way to end the pandemic and return to normal life.